NewEdge Wealth’s Ultragenyx Pharmaceutical RARE Stock Holding History

NewEdge Wealth’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,463	Closed	-$230K	–	976
2024 Q4	$230K	Sell	5,463 -482	-8%	-$23.9K	﹤0.01%	848
2024 Q3	$330K	Hold	5,945	–	–	0.01%	705
2024 Q2	$244K	Buy	+5,945	New	+$254K	0.01%	685
2021 Q2	–	Sell	-2,250	Closed	-$256K	–	304
2021 Q1	$256K	Buy	+2,250	New	+$306K	0.03%	266

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

NewEdge Wealth's RARE Position: Q1 2025 in Review

NewEdge Wealth sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 5,463 shares — an estimated $230K sold.

NewEdge Wealth first reported a position in RARE in Q1 2021 and held it in 4 quarters. The position peaked at $330K in Q3 2024. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

NewEdge Wealth reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
NewEdge Wealth sold 5,463 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $230K.
NewEdge Wealth first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and held it in 4 quarters.
NewEdge Wealth's Ultragenyx Pharmaceutical position peaked at $330K in Q3 2024.
299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on NewEdge Wealth's 13F filing for Q1 2025, filed 9 May 2025.